<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            M Michael Wolfe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 25, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proton pump inhibitors (PPIs) effectively block gastric acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the luminal surface of the parietal cell membrane.
        </p>
        <p>
         This topic review will provide an overview of the mechanism of action, pharmacokinetics, administration, and adverse effects of PPIs. The use and efficacy of PPIs in specific acid-related disorders is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/32.html" rel="external">
          "Antiulcer medications: Mechanism of action, pharmacology, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          INDICATIONS FOR PPI THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proton pump inhibitor (PPI) therapy is indicated in the following clinical situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peptic
         </strong>
         <strong>
          ulcer
         </strong>
         <strong>
          disease
         </strong>
         – PPIs are first-line antisecretory therapy in the treatment of peptic ulcer disease. (See
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention", section on 'Initial antisecretory therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastroesophageal reflux disease
         </strong>
         – PPIs are indicated in patients with gastroesophageal reflux disease, including for the treatment of erosive esophagitis and as maintenance therapy in patients with severe erosive esophagitis or Barrett’s esophagus. (See
         <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">
          "Medical management of gastroesophageal reflux disease in adults", section on 'Severe or frequent symptoms or erosive esophagitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Zollinger
         </strong>
         -
         <strong>
          Ellison
         </strong>
         <strong>
          syndrome
         </strong>
         – PPIs, often in high doses, are required to control gastric acid hypersecretion in patients with gastrin-secreting tumors.
         <strong>
         </strong>
         (See
         <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">
          "Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)", section on 'Proton pump inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          NSAID-associated ulcers
         </strong>
         – PPIs are indicated in the primary prevention of gastroduodenal ulcers associated with NSAID use. (See
         <a class="medical medical_review" href="/z/d/html/35.html" rel="external">
          "NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eradication of
         </strong>
         <strong>
          <em>
           Helicobacter pylori
          </em>
         </strong>
         – PPIs are a component of several first-line and salvage therapy regimens for
         <em>
          H. pylori
         </em>
         infection. (See
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          PHARMACOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism of action
         </strong>
         – Proton pump inhibitors (PPIs) inhibit H-K-ATPase, the final step of gastric acid secretion by parietal cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         PPIs are benzimidazole prodrugs which accumulate specifically and selectively in the secretory canaliculus of the parietal cell [
         <a href="#rid1">
          1
         </a>
         ]. Within that space, they undergo an acid catalyzed conversion to a reactive species, the thiophilic sulfonamides, which are permanent cations. The rate of conversion varies among the compounds and is inversely proportional to the pKa of the benzimidazole (
         <a class="drug drug_general" data-topicid="9519" href="/z/d/drug information/9519.html" rel="external">
          rabeprazole
         </a>
         &gt;
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">
          esomeprazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         &gt;
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          pantoprazole
         </a>
         )  (
         <a class="graphic graphic_table graphicRef72598" href="/z/d/graphic/72598.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. The reactive species interacts with the external surface of the H-K-ATPase that faces the lumen of the secretory space of the parietal cell, resulting in disulfide bond formation with cysteine 813 located within the alpha-subunit of the enzyme; this is the residue that is intimately involved in hydrogen ion transport. This covalent inhibition of the enzyme results in a specific and long-lasting impairment of gastric acid secretion. (See
         <a class="medical medical_review" href="/z/d/html/33.html" rel="external">
          "Physiology of gastric acid secretion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacokinetics
         </strong>
         – Although PPIs are similar in structure and mechanism of action, there are differences in their pharmacokinetic properties including bioavailability, peak plasma levels, half-life, and pKa  (
         <a class="graphic graphic_table graphicRef72598" href="/z/d/graphic/72598.html" rel="external">
          table 1
         </a>
         ). The magnitude of these differences are small, and their clinical relevance has not been established.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, PPIs are rapidly absorbed following oral administration. If taken with food, peak plasma concentrations may be delayed and bioavailability altered (ie, increased or decreased), depending upon the individual PPI. Most PPIs are formulated within an enteric-coating or other delayed-release system, which enables the prodrug to withstand high acidity of the gastric lumen and pass intact to absorption sites within the duodenum. Upon entering the systemic circulation, the PPI prodrug is protonated to become the active (thiophilic sulfenamide) moiety within highly acidic activated secretory canaliculus of parietal cells [
         <a href="#rid1">
          1,3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         PPIs are metabolized in the liver primarily by cytochrome P450 2C19, and to a lesser extent by CYP3A4, to inactive metabolites, which are excreted mainly in the urine and bile. The degree to which individual PPIs are dependent upon CYP2C19 activity for degradation varies and is reported to be from most to least:
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         /
         <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">
          esomeprazole
         </a>
         &gt;
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          pantoprazole
         </a>
         &gt;
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         &gt;
         <a class="drug drug_general" data-topicid="9519" href="/z/d/drug information/9519.html" rel="external">
          rabeprazole
         </a>
         [
         <a href="#rid4">
          4,5
         </a>
         ]. Despite their dependence on CYP2C19 for degradation, PPIs are themselves targets of relatively few clinically significant drug interactions. (See
         <a class="local">
          'Drug interactions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CYP2C19 activity is determined to an extent by genetic polymorphism. Approximately 5 percent of White patients and up to 20 to 30 percent of patients within certain South and East Asian populations are homozygous for a CYP2C19 mutation, thereby conferring low CYP2C19 activity (ie, slow metabolizers) [
         <a href="#rid6">
          6
         </a>
         ]. Slow metabolism of PPIs may lead to a greater duration of suppression of gastric acidity and contribute to decreased dose requirements. (See
         <a class="local">
          'Dose and timing of administration'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, one study examined the effect of variable metabolism of
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         when using this agent to treat
         <em>
          H. pylori
         </em>
         in 62 Japanese patients [
         <a href="#rid7">
          7
         </a>
         ]. While eradication was achieved in all individuals homozygous for a
         <em>
          CYP2C19
         </em>
         mutation (ie, slow metabolizers), successful treatment was achieved in only 60 and 29 percent of heterozygotes and wild type homozygotes, respectively. In another study that evaluated the efficacy of
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         in the treatment of 65 patients with gastroesophageal reflux disease (GERD), slow metabolizers were much more likely to be asymptomatic as compared with heterozygotes and wild type homozygotes (85 versus 68 and 46 percent, respectively) [
         <a href="#rid8">
          8
         </a>
         ]. The response rate in wild type homozygotes with severe GERD was only 16 percent. Wild type homozygotes (rapid metabolizers) also had the lowest plasma lansoprazole concentrations. (See
         <a class="local">
          'Dose and timing of administration'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following metabolism in the liver, PPIs are excreted as inactive metabolites in urine and in bile  (
         <a class="graphic graphic_table graphicRef72598" href="/z/d/graphic/72598.html" rel="external">
          table 1
         </a>
         ). PPI half-life (T½) is typically reported as ranging from 0.5 to 2.5 hours, which refers to half-life of the prodrug. The elimination half-life (T ½) of the active (thiophilic sulfonamide) form is greater and likely to be in the range of 12 to 18 hours. The duration of antisecretory effect of PPIs exceeds that predicted by their elimination half-life due to the stability of binding at the site of action [
         <a href="#rid1">
          1,3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pharmacokinetic properties of the PPIs are listed in a table  (
         <a class="graphic graphic_table graphicRef72598" href="/z/d/graphic/72598.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacodynamics -
         </strong>
         PPIs are most effective when the parietal cell is stimulated to secrete acid postprandially, a relationship that has important clinical implications for timing of administration. Because the amount of H-K-ATPase present in the parietal cell is greatest after a prolonged fast, PPIs should be administered before the first meal of the day. In most individuals, once-daily dosing is sufficient to produce the desired level of acid inhibition, and a second dose, which is occasionally necessary, should be administered before the evening meal [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Dose and timing of administration'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once-daily PPI dosing for five days inhibits maximal gastric acid output by approximately 66 percent. Since PPIs inhibit only activated enzyme present in the canalicular membrane, the reduction of gastric acid secretion after an initial dose will probably be suboptimal. As inactive enzyme is recruited into the secretory canaliculus, acid secretion will resume, albeit at a reduced level. After the second dose is given on the next day, more H-K-ATPase will have been recruited and subsequently inhibited, and after the third dose, additional recruitment and further acid inhibition will probably occur. Thus, the occasional use of a PPI taken on an "as needed" basis does not reliably provide adequate acid inhibition and does not produce a consistent or satisfactory clinical response (in contrast to the H2 antagonists, which have a more rapid onset of action) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Restoration of acid secretion after discontinuing PPIs depends upon enzyme turnover and the biological reversibility of the disulfide bond. Maximal acid secretory capacity may not be restored for 24 to 48 hours [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Discontinuing PPIs'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3989414815">
         <span class="h1">
          PRETREATMENT CONSIDERATIONS AND MONITORING
         </span>
        </p>
        <p class="headingAnchor" id="H2942254740">
         <span class="h2">
          Drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the proton pump inhibitors (PPIs) are rarely the target of clinically relevant drug-drug interactions, UpToDate suggests avoiding their administration at the same time as antisecretory agents (eg, histamine-2 receptor antagonists [H2RAs]) due to decreased acid-inhibitory effects (see
         <a class="local">
          'Avoidance of concurrent antisecretory agents'
         </a>
         below). Furthermore, strong inducers of CYP2C19 (eg,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ) can result in decreased efficacy of some of the PPIs (
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">
          esomeprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         ); coadministration of these PPIs with rifampin should be avoided [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         PPIs are implicated in decreasing the oral bioavailability of some co-medications via modulation of gastric acidity and, in some cases, can interact via inhibition of CYP2C19 metabolism. Illustrative examples of impaired absorption of an oral co-medication due to PPI modulation of gastric acidity include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Azole antifungals (some)
         </strong>
         – PPIs can decrease oral bioavailability of certain azole formulations:
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         oral suspension and conventional
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         capsules (Sporanox brand) [
         <a href="#rid11">
          11-13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles", section on 'Drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HCV direct acting antivirals (some)
         </strong>
         – PPIs can decrease absorption of velpatasvir- and ledipasvir-containing regimens. (See
         <a class="medical medical_review" href="/z/d/html/93242.html" rel="external">
          "Direct-acting antivirals for the treatment of hepatitis C virus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV antiretrovirals (some) –
         </strong>
         Due to impaired absorption of
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         , combined use with a PPI is contraindicated; the use of
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         should be avoided in patients who require
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         dose of &gt;20 mg daily or equivalent. (See
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycophenolate
         </strong>
         <strong>
          mofetil –
         </strong>
         PPIs can decrease absorption of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF) by 25 percent or more [
         <a href="#rid14">
          14
         </a>
         ]. Enteric-coated mycophenolate sodium (EC-MPS) formulation appears less likely to interact. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tyrosine kinase inhibitors (TKIs) (several)
         </strong>
         – Diminished total exposure (AUC
         <sub>
          0-24
         </sub>
         ) by up to 78 percent has been reported for the TKI
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         when coadministered with a PPI [
         <a href="#rid15">
          15
         </a>
         ]. This interaction may also occur with other TKIs that require gastric acidity to solubilize and become absorbed (eg,
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         capsules [acalabrutinib tablets do not interact with PPIs],
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="119171" href="/z/d/drug information/119171.html" rel="external">
          dacomitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">
          gefitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="131754" href="/z/d/drug information/131754.html" rel="external">
          infigratinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">
          neratinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         ,
         <a class="drug drug_general" data-topicid="122066" href="/z/d/drug information/122066.html" rel="external">
          pexidartinib
         </a>
         ). Additional information is available elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4630.html" rel="external">
          "Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor", section on 'Erlotinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Additional information on drug interactions due to PPI gastric acidity modulation is provided in a table  (
         <a class="graphic graphic_table graphicRef53616" href="/z/d/graphic/53616.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Illustrative examples of altered exposure of a co-medication due to PPI inhibition of CYP2C19 metabolism include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clopidogrel
         </strong>
         <strong>
          –
         </strong>
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          Clopidogrel
         </a>
         requires conversion to its active form via CYP2C19 metabolism. Some data suggest decreased activation of clopidogrel when used in conjunction with
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         due to shared hepatic CYP2C19 metabolism.
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          Pantoprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9519" href="/z/d/drug information/9519.html" rel="external">
          rabeprazole
         </a>
         appear less likely to interact. In 2009, the US Food and Drug Administration (FDA) concluded that patients taking clopidogrel should consult with their clinician if they are taking or considering taking a PPI, including over-the-counter PPI preparations [
         <a href="#rid16">
          16,17
         </a>
         ]. However, the relevance of these data remains highly controversial. We advise patients requiring PPI therapy who take clopidogrel not to use omeprazole or
         <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">
          esomeprazole
         </a>
         and to take the PPI in the morning and clopidogrel at least four hours later, eg, at bedtime [
         <a href="#rid18">
          18
         </a>
         ]. Additional detail of this interaction is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">
          "Clopidogrel resistance and clopidogrel treatment failure", section on 'Interaction with other drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Citalopram
         </strong>
         <strong>
          –
         </strong>
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          Omeprazole
         </a>
         can increase total exposure (AUC
         <sub>
          0-24
         </sub>
         hours) to the active form of
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         by 90 percent via inhibition of CYP2C19 metabolism [
         <a href="#rid19">
          19
         </a>
         ]. The labeling recommends limiting the citalopram dose to 20 mg/day if used with omeprazole.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cilostazol
         </strong>
         <strong>
          –
         </strong>
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          Omeprazole
         </a>
         can increase serum concentrations of
         <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">
          cilostazol
         </a>
         via inhibition of CYP2C19 metabolism [
         <a href="#rid20">
          20
         </a>
         ]. A dose adjustment of cilostazol is recommended if used with omeprazole.
        </p>
        <p>
        </p>
        <p>
         Other drug interactions observed with PPIs include the following; the mechanism for these interactions is not well established:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Methotrexate
         </strong>
         <strong>
          –
         </strong>
         Coadministration of PPIs with high dose
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         appears to be correlated with delayed methotrexate elimination and potentially may lead to methotrexate toxicity if not monitored appropriately [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">
          "Therapeutic use and toxicity of high-dose methotrexate", section on 'Potential drug-drug-interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Warfarin
         </strong>
         <strong>
          –
         </strong>
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          Lansoprazole
         </a>
         and
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         have been associated with modest increases in serum concentrations of R-warfarin (ie, less active
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         enantiomer) in a number of case reports [
         <a href="#rid22">
          22-24
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additional information on drug interactions due to PPI inhibition of CYP2C19 metabolism and other mechanisms is provided in a table  (
         <a class="graphic graphic_table graphicRef53616" href="/z/d/graphic/53616.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         This is
         <strong>
          not
         </strong>
         a complete list of PPI drug interactions. For additional information on specific drug interactions, use the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="headingAnchor" id="H1860854596">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We limit routine laboratory testing to selected patients on PPI therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Magnesium
         </strong>
         – We obtain serum magnesium levels prior to starting a PPI in patients who are expected to be on long-term (≥1 year) treatment or in patients who take PPIs in conjunction with other medications associated with hypomagnesemia (eg, diuretics). In addition, we obtain magnesium levels periodically in such patients while they are taking a PPI. The frequency of testing is based on the clinical history and the presence of symptoms of hypomagnesemia. As an example, in patients with a history of arrhythmias or QT interval prolongation, we monitor magnesium levels every six months. The management of hypomagnesemia is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/834.html" rel="external">
          "Hypomagnesemia: Evaluation and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin B12
         </strong>
         – We also obtain vitamin B12 levels yearly in patients on long-term PPIs [
         <a href="#rid25">
          25
         </a>
         ]. However, routinely monitoring vitamin B12 levels is controversial. (See
         <a class="local">
          'Magnesium malabsorption'
         </a>
         below and
         <a class="local">
          'Vitamin B12 malabsorption'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         There are insufficient evidence to support routine bone density monitoring or calcium supplementation due to proton pump inhibitor use alone [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H102540293">
         <span class="h1">
          ADMINISTRATION
         </span>
        </p>
        <p class="headingAnchor" id="H1479116065">
         <span class="h2">
          Intravenous regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         IV PPIs are indicated prior to endoscopic evaluation in patients with clinically significant upper gastrointestinal bleeding from a suspected peptic ulcer.
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          Pantoprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9104" href="/z/d/drug information/9104.html" rel="external">
          esomeprazole
         </a>
         are the only PPIs available as an IV formulation in the United States; IV
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         is available in other countries. The use of PPIs in the treatment of bleeding peptic ulcers and the duration of treatment is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2573.html" rel="external">
          "Overview of the treatment of bleeding peptic ulcers", section on 'Oral versus intravenous dosing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">
          "Approach to acute upper gastrointestinal bleeding in adults", section on 'Acid suppression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3507771654">
         <span class="h2">
          Oral regimen
         </span>
        </p>
        <p class="headingAnchor" id="H3130884335">
         <span class="h3">
          Selecting a PPI
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of a specific oral PPI and whether over-the-counter (rather than prescription) PPIs are prescribed are often determined by patient preference and payer coverage. A systematic review of 12 randomized trials examining the relative effectiveness of different PPI doses and dosing regimens found no consistent difference in symptom resolution and esophagitis healing rates [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         In patients unable to swallow pills or capsules, options include an orally disintegrating tablet (ODT) of
         <a class="drug drug_general" data-topicid="9546" href="/z/d/drug information/9546.html" rel="external">
          lansoprazole
         </a>
         , delayed-release granules (packets) of
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          pantoprazole
         </a>
         for oral suspension, and a
         <a class="drug drug_general" data-topicid="9519" href="/z/d/drug information/9519.html" rel="external">
          rabeprazole
         </a>
         capsule that can be opened and sprinkled on soft food.
        </p>
        <p class="headingAnchor" id="H745155432">
         <span class="h3">
          Dose and timing of administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPIs should be administered 30 to 60 minutes before breakfast for maximal inhibition of proton pumps. (See
         <a class="local">
          'Pharmacology'
         </a>
         above.)
        </p>
        <p>
         Dose reduction, particularly for maintenance of healing of erosive esophagitis may be possible in Asian populations. Polymorphisms in the
         <em>
          CYP2C19
         </em>
         gene, which encodes the cytochrome P450 isoenzyme that metabolizes different PPI preparations, are common in Asian and other populations [
         <a href="#rid28">
          28
         </a>
         ]. Such gene mutations would render an individual a "slow metabolizer" and prolong the antisecretory effect of PPIs. In contrast, the duration of acid inhibition would be decreased in a "rapid metabolizer," and differences in PPI metabolism might account for incomplete inhibition of acid secretion and a high prevalence of nocturnal breakthrough symptoms in gastroesophageal reflux disease patients. (See
         <a class="local">
          'Pharmacology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">
          "Approach to refractory gastroesophageal reflux disease in adults", section on 'Differences in PPI metabolism'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3714600972">
         <span class="h3">
          Avoidance of concurrent antisecretory agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPIs should not administered concomitantly with antisecretory agents including histamine-2 receptor antagonists (H2RAs), analogues of prostaglandin E (eg,
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         ), and somatostatin analogues (eg,
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         ), because of the marked reduction in acid inhibitory effects [
         <a href="#rid1">
          1,29
         </a>
         ]. Antisecretory drugs can be used with a PPI provided that there is a sufficient time interval between their administration. As an example, an H2RA can be taken before bedtime or during the night by individuals who report nocturnal breakthrough symptoms such as heartburn after taking a PPI in the morning or before dinner.
        </p>
        <p class="headingAnchor" id="H3193407225">
         <span class="h3">
          Switching between PPIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Switching PPIs is a reasonable strategy in patients with side-effects to an individual PPI and may be necessary due to cost differences. Although there is significant interindividual and intraindividual variability in intragastric pH control between PPIs, there are no consistent difference in relation to symptom resolution and esophagitis healing rates [
         <a href="#rid27">
          27
         </a>
         ]. Switching PPIs in patients with well-controlled symptoms may also be associated with increased symptom severity and decreased patient satisfaction [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2239.html" rel="external">
          "Approach to refractory gastroesophageal reflux disease in adults", section on 'Subsequent management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1150172641">
         <span class="h3">
          Discontinuing PPIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPIs should be prescribed at the lowest dose and for the shortest duration appropriate to the condition being treated. (See
         <a class="local">
          'Indications for PPI therapy'
         </a>
         above.)
        </p>
        <p>
         We gradually taper PPI therapy in patients treated with PPIs for longer than six months. For patients on a standard or high-dose PPI (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         40 mg daily or twice daily), we decrease the dose by 50 percent every week. For patients on twice daily dosing, the initial reduction can be accomplished by decreasing the dosing to once in the morning before breakfast until the patient is on the lowest dose of the medication. Once on the lowest dose for one week, the patient is instructed to discontinue the PPI. However, no specific method for discontinuing PPI therapy has been proven effective, and no approach is universally accepted. [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         Studies have demonstrated rebound gastric acid hypersecretion following discontinuation of PPIs in patients with long-term use. The reasons are not entirely clear, but appear to be due in part to the suppression of antral somatostatin expression, resulting in an increase in antral gastrin release and subsequent disruption of normal pH-related feedback inhibition of acid secretion that occurs after a meal [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/33.html" rel="external">
          "Physiology of gastric acid secretion", section on 'Tolerance'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H59974871">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term PPI use has been associated with several safety concerns. However, few of these concerns are supported by consistent data demonstrating a causal relationship. (See
         <a class="medical medical_review" href="/z/d/html/2551.html" rel="external">
          "Physiology of gastrin", section on 'Hypergastrinemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H59976608">
         <span class="h2">
          Gastrointestinal effects
         </span>
        </p>
        <p class="headingAnchor" id="H59974951">
         <span class="h3">
          Clostridioides difficile and other enteric infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPI use has been associated with an increased risk of
         <em>
          C. difficile
         </em>
         infection, even in the absence of antibiotic use [
         <a href="#rid33">
          33-43
         </a>
         ]. Associations with other enteric infections, including salmonellosis and campylobacteriosis, have also been reported [
         <a href="#rid44">
          44-49
         </a>
         ]. However, the pathophysiologic mechanism involved in the increased risk of infection is unclear.
        </p>
        <p>
         A 2017 meta-analysis of 50 observational studies found that PPI use was significantly associated with an increased risk of
         <em>
          C. difficile
         </em>
         infection (relative risk [RR] 1.3; 95% CI 1.1-14). The risk of
         <em>
          C. difficile
         </em>
         infection appears to be greater with PPIs as compared to histamine-2 receptor antagonists (H2RAs) [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
         PPI use has also been associated with an increased risk of recurrent
         <em>
          C. difficile
         </em>
         infection [
         <a href="#rid41">
          41
         </a>
         ]. In a 2017 meta-analysis of 16 observational studies that included 7703 patients with
         <em>
          C. difficile
         </em>
         infection of whom 1525 (20 percent) had recurrent
         <em>
          C. difficile
         </em>
         infection, gastric acid suppression was significantly associated with an increased risk of recurrent
         <em>
          C. difficile
         </em>
         infection (odds ratio [OR] 1.5; 95% CI 1.2-1.9) [
         <a href="#rid50">
          50
         </a>
         ]. There was significant heterogeneity among the studies included in the meta-analysis. In adjusted analysis using data from nine studies, PPI use was associated with an increased risk of recurrent
         <em>
          C. difficile
         </em>
         infection after controlling for patient age and other co-morbid conditions (OR 1.4; 95% CI 1.1-1.8). (See
         <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">
          "
          <i>
           Clostridioides difficile
          </i>
          infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Gastric acid suppression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1458532162">
         <span class="h3">
          Microscopic colitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPI use has been associated with microscopic colitis, including lymphocytic and collagenous colitis. In a case-control study that included 95 cases of microscopic colitis, exposure to PPIs was significantly higher in patients with microscopic colitis as compared with controls (38 versus 13 percent, OR 4.5, 95% CI 2.0-9.5) [
         <a href="#rid51">
          51
         </a>
         ]. Similar results have been reported in other case-control studies, however, it is unclear if this association varies by PPI and if there is a dose-response relationship in either dose or duration of use [
         <a href="#rid52">
          52,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">
          "Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2701428744">
         <span class="h3">
          Hypergastrinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Induction of hypergastrinemia has been associated with gastric carcinoid tumors in rats. However, these observations are not generalizable to species with gastrin physiology more analogous to humans [
         <a href="#rid54">
          54
         </a>
         ]. While patients treated with
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         for up to 11 years have shown some enterochromaffin-like cell hyperplasia, no dysplasia or neoplastic changes have been observed [
         <a href="#rid55">
          55
         </a>
         ]. An increased risk of colon cancer due to hypergastrinemia has also not been established [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2551.html" rel="external">
          "Physiology of gastrin"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1117261445">
         <span class="h3">
          Atrophic gastritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients on long-term PPI therapy have a propensity to develop chronic atrophic gastritis. However, the risk of atrophic gastritis is small, and in the rare patient who develops atrophic gastritis, the clinical consequences are uncertain [
         <a href="#rid55">
          55,57,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2617.html" rel="external">
          "Risk factors for gastric cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2676750489">
         <span class="h3">
          Intestinal colonization of multi-drug resistant organisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPIs may increase the risk of intestinal colonization with multi-drug resistant organisms. In a meta-analysis of 12 observational studies that included 22,305 patients, after adjusting for potential confounders, acid suppression increased the odds of intestinal carriage of multi-drug resistant organisms of the
         <em>
          Enterobacterales
         </em>
         order (producing extended-spectrum beta-lactamases, carbapenemases, or plasmid-mediated AmpC beta-lactamases) and of vancomycin-resistant enterococci (OR 1.74; 95% CI 1.4-2.2) [
         <a href="#rid59">
          59
         </a>
         ]. Possible mechanisms include an increase in bacteria that survive transit from the stomach to the intestine due to reduction in gastric acid by PPIs and direct alteration of the composition of intestinal microbiota, leading to a decrease in mean species diversity.
        </p>
        <p class="headingAnchor" id="H2177604798">
         <span class="h3">
          Inflammatory bowel disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a study that pooled data from three observational cohorts and included &gt;600,000 individuals followed for a median of 12 years, the risk of inflammatory bowel disease (IBD) was increased in regular PPI users as compared with nonusers (hazard ratio [HR] 1.42; 95% CI 1.22–1.65) [
         <a href="#rid60">
          60
         </a>
         ]. However, the absolute risk of IBD was low, with a number needed to harm of 3770. In addition, absence of data on PPI dosing precluded assessment of a dose-response relationship between PPI use and IBD.
        </p>
        <p class="headingAnchor" id="H59976220">
         <span class="h2">
          Malabsorption of minerals and vitamins
         </span>
        </p>
        <p class="headingAnchor" id="H59977009">
         <span class="h3">
          Magnesium malabsorption
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPIs can cause hypomagnesemia due to reduced intestinal absorption [
         <a href="#rid61">
          61
         </a>
         ]. A meta-analysis of nine observational studies that included a total of 109,798 patients found that those who took a PPI had a significantly higher risk (RR 1.43; 95% CI 1.08-1.88) of developing hypomagnesemia as compared with those who did not [
         <a href="#rid62">
          62
         </a>
         ]. Clinical manifestations of hypomagnesemia include neuromuscular excitability (eg, tremor, tetany, convulsions), weakness, and apathy. Severe PPI-induced hypomagnesemia has been associated with QT interval prolongation and torsades de pointes [
         <a href="#rid63">
          63,64
         </a>
         ]. The risk of hypomagnesemia appears to be mainly in patients who have been on PPIs long-term (generally longer than one year) but cases have been reported within one year of starting PPI therapy [
         <a href="#rid63">
          63,65
         </a>
         ]. This potential risk has led to recommendations to monitor serum magnesium levels in specific patients at high risk for hypomagnesemia. Monitoring for hypomagnesemia in patients on PPIs is discussed in detail separately. (See
         <a class="local">
          'Laboratory testing'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion", section on 'Overview of clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H59976497">
         <span class="h3">
          Calcium and fracture risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although hypochlorhydria could theoretically reduce calcium absorption, the effect appears to be relevant only for the absorption of water insoluble calcium (eg,
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         ) and can be overcome by ingestion of a slightly acidic meal [
         <a href="#rid66">
          66
         </a>
         ]. The absorption of water-soluble calcium salts or calcium in dairy products are not impacted by PPI-induced hypochlorhydria. When calcium supplementation is necessary in patients taking PPIs, we use calcium supplements that do not require acid for absorption, such as
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          calcium citrate
         </a>
         . (See
         <a class="local">
          'Laboratory testing'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">
          "Drugs that affect bone metabolism", section on 'Proton pump inhibitors'
         </a>
         .)
        </p>
        <p>
         PPI-induced hypochlorhydria can augment osteoclastic activity, thereby decreasing bone density [
         <a href="#rid67">
          67,68
         </a>
         ]. Although an association between PPI use and bone fracture is plausible, causality has not been established [
         <a href="#rid69">
          69
         </a>
         ]. Nonetheless, the FDA has mandated revised safety information on all PPIs about a possible increased risk of fractures of the hip, wrist, and spine with the use of these medications [
         <a href="#rid70">
          70
         </a>
         ]. The association between PPIs and bone metabolism and risk of fracture are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2036.html" rel="external">
          "Drugs that affect bone metabolism", section on 'Proton pump inhibitors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H59976227">
         <span class="h3">
          Vitamin B12 malabsorption
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-term therapy with PPIs has been associated with vitamin B12 malabsorption [
         <a href="#rid71">
          71,72
         </a>
         ]. However, absorption of oral B12 supplements is not affected. (See
         <a class="local">
          'Laboratory testing'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">
          "Treatment of vitamin B12 and folate deficiencies", section on 'Treatment of vitamin B12 deficiency'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H59976234">
         <span class="h3">
          Iron malabsorption
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastric acid plays a role in the absorption of nonheme iron, and the use of PPIs has been associated with decreased iron absorption [
         <a href="#rid73">
          73-77
         </a>
         ]. However, in most cases the decreased absorption does not appear to be of clinical significance. One exception may be in patients who require oral iron supplementation [
         <a href="#rid76">
          76,78
         </a>
         ]. Such patients may need a higher dose or longer duration of supplementation [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults", section on 'Dosing and administration (oral iron)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H876746377">
         <span class="h2">
          Kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPIs can cause acute interstitial nephritis (AIN) [
         <a href="#rid79">
          79-82
         </a>
         ]. Similar to other cases of drug-induced AIN, AIN due to PPI use is not dose-dependent, and recurrence or exacerbation can occur with a second exposure to the same or a related drug. (See
         <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">
          "Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'Drugs'
         </a>
         .)
        </p>
        <p>
         PPI use has also been associated with an increased risk of incident chronic kidney disease (CKD), CKD progression, and end-stage kidney disease [
         <a href="#rid83">
          83-86
         </a>
         ]. However, the mechanism underlying the association between PPI use and risk of CKD is not known, and it is possible that the weak association observed in these studies is due to methodological limitations (residual confounding) [
         <a href="#rid83">
          83,84,87
         </a>
         ]. Further studies are needed to help better define an etiologic relationship between PPI use and the development and worsening of CKD.
        </p>
        <p class="headingAnchor" id="H3622237338">
         <span class="h2">
          Drug-induced lupus
         </span>
         <span class="headingEndMark">
          —
         </span>
         In postmarketing safety surveillance, new onset of cutaneous lupus erythematosus and systemic lupus erythematosus (SLE), and exacerbation of existing disease have been reported in patients on PPIs [
         <a href="#rid88">
          88-90
         </a>
         ]. Most cases of CLE-associated with PPI use are subacute and occur within weeks to years after continuous PPI therapy. PPI-associated SLE usually occurs days to years after initiating PPI treatment and typically presents with a rash. Most patients improve within 4 to 12 weeks of discontinuation of PPI therapy. (See
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus", section on 'Causative drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2967079585">
         <span class="h2">
          Other associations of unclear significance
         </span>
        </p>
        <p class="headingAnchor" id="H4803415">
         <span class="h3">
          COVID-19
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is unclear if PPI use is associated with an increased risk of COVID-19. In a cross-sectional survey of 86,602 individuals, 53,130 reported prior abdominal pain, acid reflux, heartburn, and regurgitation symptoms and provided data on H2RA and PPI use. Of these, 3386 individuals (6.4 percent) self-reported a positive COVID-19 test [
         <a href="#rid91">
          91
         </a>
         ]. In analyses adjusted for socioeconomic, lifestyle, and clinical comorbidities, patients who reported PPI use were significantly more likely to report a positive COVID-19 test with a dose-dependent increase in odds of reporting a positive test (PPI once-daily OR 2.15, 95% CI 1.9-2.4; PPI twice-daily OR 3.7, 95% CI 2.9-4.6). It is possible that this association is due to residual confounding.
        </p>
        <p>
         Other studies have demonstrated that patients taking PPIs are at increased risk for severe clinical outcomes of COVID-19 but have not demonstrated an increase in susceptibility to SARS-CoV-2 infection [
         <a href="#rid92">
          92
         </a>
         ]. These data require further validation.
        </p>
        <p class="headingAnchor" id="H3416958771">
         <span class="h3">
          Dementia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although some studies have found a significant association between use of PPIs and incident dementia, others have not found an association between PPI use and cognitive function [
         <a href="#rid93">
          93-98
         </a>
         ]. The association between PPI use and dementia may reflect residual confounding by factors related to both use of PPIs and the development of dementia and is discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/16575.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of Alzheimer disease", section on 'Medications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2745364464">
         <span class="h3">
          Pneumonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         While observational studies suggest an association between PPI use and pneumonia, the observed association may be due to confounding such that individuals prescribed PPIs may be more likely to have other unobserved health characteristics that predispose them to pneumonia as compared with nonusers [
         <a href="#rid99">
          99-106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">
          "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults", section on 'Predisposing host conditions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6995.html" rel="external">
          "Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Role of gastric pH'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3309582559">
         <span class="h3">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is unclear if PPI use is associated with an increase in risk of death. In an observational cohort study that included 275,977 new PPI users and 73,335 new histamine-2 receptor antagonist (H2RA) users, over a median follow-up of 5.7 years, the incident death rate among new PPI users was higher as compared to those receiving H2RA (4.5 versus 3.3 per 100 person-years) [
         <a href="#rid107">
          107
         </a>
         ]. New PPI users were significantly older as compared with new users of H2RAs at the time of study entry (61.7 versus 58.5 years). However, after adjusting for potential confounders, PPI use was associated with an increase in all-cause mortality as compared with H2RA use (HR 1.25, 95% CI 1.23-1.28). PPI users also had an increase in risk of death as compared with individuals without any PPI use and individuals without any acid suppression use (HR 1.15, 95% CI 1.14-1.15; HR 1.23, 95% CI 1.22-1.24, respectively). Among new PPI users, the risk of death increased with the duration of PPI use. Limitations of the study include its generalizability as the study cohort primarily consisted of older White males, and lack of data on the cause of mortality. The underlying basis for this apparent increased risk of death with PPI use are not known and further studies are needed to evaluate whether this epidemiologic association is due to unmeasured confounding.
        </p>
        <p class="headingAnchor" id="H2402277">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15325.html" rel="external">
          "Patient education: Acid reflux and GERD in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2011.html" rel="external">
          "Patient education: Gastroesophageal reflux disease in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for proton pump inhibitors
         </strong>
         – Indications include the treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Proton pump inhibitors (PPIs) are effective in the prevention of nonsteroidal anti-inflammatory drug-associated gastroduodenal mucosal injury and are an important component of several antimicrobial regimens used in the treatment of
         <em>
          Helicobacter pylori
         </em>
         infection. (See
         <a class="local">
          'Indications for PPI therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacology
         </strong>
         – PPIs effectively block gastric acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the luminal surface of the parietal cell membrane. Genetically determined variability in the PPI metabolism can influence their efficacy. The presence of a
         <em>
          CYP2C19
         </em>
         gene mutation can result in higher plasma PPI levels in homozygous individuals. PPI metabolism via hepatic cytochrome P450 enzymes may lead to specific drug interactions in some individuals. However, clinically important drug interactions with PPIs are infrequent. (See
         <a class="local">
          'Pharmacology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Oral PPIs should be administered 30 to 60 minutes before breakfast for maximal inhibition of proton pumps. PPIs should not be administered concomitantly with histamine-2 receptor antagonists (H2RAs), and prostaglandins or somatostatin analogues. The magnitude of pharmacokinetic differences between PPIs is small and the clinical relevance of these differences has not been established  (
         <a class="graphic graphic_table graphicRef72598" href="/z/d/graphic/72598.html" rel="external">
          table 1
         </a>
         ). Intravenous PPI therapy is indicated in patients with clinically significant upper gastrointestinal bleeding prior to endoscopy for treatment of suspected bleeding peptic ulcers. In general, PPIs should be prescribed at the lowest dose and for the shortest duration appropriate to the condition being treated. When discontinuing PPI therapy, we taper the dose gradually in patients on PPIs for longer than six months. (See
         <a class="local">
          'Administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gastrointestinal
         </strong>
         – PPI use has been associated with an increased risk of
         <em>
          Clostridioides
         </em>
         <em>
          difficile
         </em>
         infection, other enteric infections, and microscopic colitis.
         <em>
          C. difficile
         </em>
         infection with diarrhea may occur even in the absence of antibiotic use. (See
         <a class="local">
          'Gastrointestinal effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Malabsorption of minerals and vitamins
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         PPIs can cause hypomagnesemia due to reduced intestinal absorption. Long-term therapy with PPIs has been associated with vitamin B12 malabsorption. We obtain serum magnesium levels prior to starting a PPI in patients who are expected to be on long-term (≥1 year) treatment, or in patients who take PPIs in conjunction with other medications associated with hypomagnesemia. In addition, we also monitor magnesium and vitamin B12 levels in patients on long-term PPIs. (See
         <a class="local">
          'Pretreatment considerations and monitoring'
         </a>
         above and
         <a class="local">
          'Magnesium malabsorption'
         </a>
         above and
         <a class="local">
          'Vitamin B12 malabsorption'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Although an association between PPIs and bone fracture is plausible, causality has not been established. PPIs can decrease the absorption of water insoluble calcium (eg,
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         ). When calcium supplementation is necessary in patients taking PPIs, we use calcium supplements that do not require acid for absorption, such as
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          calcium citrate
         </a>
         . (See
         <a class="local">
          'Calcium and fracture risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Kidney disease
         </strong>
         – PPIs can cause acute interstitial nephritis. PPI use has also been associated with an increased risk of incident chronic kidney disease (CKD), CKD progression, and end-stage renal disease. However, further studies are needed to help better define an etiologic relationship between PPI use and the development and worsening of CKD. (See
         <a class="local">
          'Kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Associations of unclear significance
         </strong>
         – There are conflicting data on the association between PPI use and risk of dementia and pneumonia. It is also unclear if PPI use is associated with an increased risk of death. It is possible that these associations are due to residual confounding and more studies are needed. (See
         <a class="local">
          'Kidney disease'
         </a>
         above and
         <a class="local">
          'Dementia'
         </a>
         above and
         <a class="local">
          'Mortality'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118:S9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004; 126:7800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013; 19:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014; 37:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008; 47:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koopmans AB, Braakman MH, Vinkers DJ, et al. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry 2021; 11:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park GJ, Bae SH, Park WS, et al. Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. Drug Des Devel Ther 2017; 11:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanebratt KP, Diczfalusy U, Bäckström T, et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 2008; 84:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson MD, Hamilton CD, Drew RH, et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003; 51:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford) 2010; 49:2061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yago MR, Frymoyer A, Benet LZ, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J 2014; 16:1358.
          </a>
         </li>
         <li class="breakAll">
          Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available on the US Food and Drug Administration (FDA) web site: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm (Accessed on November 18, 2009).
         </li>
         <li class="breakAll">
          FDA's MedWatch Safety Alerts: November 2009. Plavix and Prilosec Drug Interaction. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm192103.htm#PlavixandPrilosecDrugInteraction (Accessed on January 26, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 2009; 120:2310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol 2010; 70:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37 Suppl 2:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beorlegui B, Aldaz A, Ortega A, et al. Potential interaction between methotrexate and omeprazole. Ann Pharmacother 2000; 34:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg 2008; 56:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unge P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad S. Omeprazole-warfarin interaction. South Med J 1991; 84:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology 2017; 152:706.
          </a>
         </li>
         <li class="breakAll">
          Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on December 05, 2007).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe MM, Lowe RC. Investing in the future of GERD. J Clin Gastroenterol 2007; 41:S209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Graef J, Woussen-Colle MC. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology 1986; 91:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson WW, Vermeulen LC, Geurkink EA, et al. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med 2000; 160:2491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Björnsson E, Abrahamsson H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011; 124:276.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103:2308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaishnavi C. Established and potential risk factors for Clostridum difficile infection. Indian J Med Microbiol 2009; 27:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect 2018; 98:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996; 312:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kader SA, Mansour AM, Mohran Z, et al. A study on the relation between proton pump inhibitor and gastric giardiasis. J Egypt Soc Parasitol 1998; 28:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynaert H, Fernandes E, Bourgain C, et al. Proton-pump inhibition and gastric giardiasis: a causal or casual association? J Gastroenterol 1995; 30:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García Rodríguez LA, Ruigómez A, Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia Rodríguez LA, Ruigómez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology 1997; 8:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. Epidemiol Infect 2017; 145:1617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tariq R, Singh S, Gupta A, et al. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010; 32:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Law EH, Badowski M, Hung YT, et al. Association Between Proton Pump Inhibitors and Microscopic Colitis. Ann Pharmacother 2017; 51:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhaegh BP, de Vries F, Masclee AA, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016; 43:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Ann Intern Med 1994; 121:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Soest EM, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999; 117:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willems RPJ, van Dijk K, Ket JCF, Vandenbroucke-Grauls CMJE. Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms: A Systematic Review and Meta-analysis. JAMA Intern Med 2020; 180:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xia B, Yang M, Nguyen LH, et al. Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts. Gastroenterology 2021; 161:1842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012; 36:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015; 37:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010; 56:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen BA, Bruserud Ø. Hypomagnesemia as a potentially life-threatening adverse effect of omeprazole. Oxf Med Case Reports 2016; 2016:147.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm (Accessed on March 02, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985; 313:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuukkanen J, Väänänen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986; 38:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012; 344:e372.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213321.htm (Accessed on June 02, 2010).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994; 120:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013; 310:2435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009; 104 Suppl 2:S5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007; 56:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011; 56:2349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther 2012; 19:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. Gastroenterology 2017; 152:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004; 97:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol 2013; 23:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ra A, Tobe SW. Acute interstitial nephritis due to pantoprazole. Ann Pharmacother 2004; 38:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006; 4:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis 2014; 64:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie Y, Bowe B, Li T, et al. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol 2016; 27:3153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med 2016; 176:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo HW, Tsai SS, Tiao MM, et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010; 19:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007; 120:280.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klatte DCF, Gasparini A, Xu H, et al. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology 2017; 153:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal N. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors. Drugs Real World Outcomes 2016; 3:145.
          </a>
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021153s052_22101s016_21957s019lbl.pdf (Accessed on November 09, 2016).
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (Accessed on November 09, 2016).
         </li>
         <li class="breakAll">
          Alamario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. AM J Gastro. 2020 [in press]. https://journals.lww.com/ajg/Documents/AJG-20-1811_R1(PUBLISH%20AS%20WEBPART).pdf (Accessed on July 13, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021; 70:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015; 265:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia. JAMA Neurol 2016; epub.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lochhead P, Hagan K, Joshi AD, et al. Association Between Proton Pump Inhibitor Use and Cognitive Function in Women. Gastroenterology 2017; 153:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batchelor R, Gilmartin JF, Kemp W, et al. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. J Gastroenterol Hepatol 2017; 32:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein FC, Steenland K, Zhao L, et al. Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia. J Am Geriatr Soc 2017; 65:1969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MA, Yuan Y, Iqbal U, et al. No Association Linking Short-Term Proton Pump Inhibitor Use to Dementia: Systematic Review and Meta-analysis of Observational Studies. Am J Gastroenterol 2020; 115:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013; 28:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedberg DE, Abrams JA. Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea? Am J Gastroenterol 2013; 108:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myles PR, Hubbard RB, McKeever TM, et al. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009; 18:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie Y, Bowe B, Li T, et al. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open 2017; 7:e015735.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5 Version 54.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10868896" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15212527" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23350044" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24550106" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18076214" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33627619" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9867757" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12386647" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28408803" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18650803" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075045" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9626921" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of omeprazole on the pharmacokinetics of itraconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12562722" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20671023" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25274610" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25274610" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25274610" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19933929" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Proton pump inhibitors and clopidogrel: putting the interaction in perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20642546" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10702887" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of omeprazole on the metabolism of cilostazol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10981249" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Potential interaction between methotrexate and omeprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18615373" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1493083" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A study of the interaction of omeprazole and warfarin in anticoagulated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2035104" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Omeprazole-warfarin interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10848649" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28257716" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28257716" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Investing in the future of GERD
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2873074" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10979061" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16948806" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11677201" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Step-down management of gastroesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21396512" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20458086" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18702653" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19736396" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Established and potential risk factors for Clostridum difficile infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15238493" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12855243" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16414946" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17509031" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Systematic review of the risk of enteric infection in patients taking acid suppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22525304" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22710578" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28842261" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8601113" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9617051" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A study on the relation between proton pump inhibitor and gastric giardiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8963397" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Proton-pump inhibition and gastric giardiasis: a causal or casual association?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18054750" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9270961" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28325163" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Proton pump inhibitors as a risk factor for norovirus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28346595" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21039674" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27733667" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Association Between Proton Pump Inhibitors and Microscopic Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26956016" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8017751" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Omeprazole, hypergastrinemia, and gastric carcinoid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10734017" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18070237" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Proton pump inhibitors and the risk of colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8598839" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10419912" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32091544" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34389338" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22762246" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Systematic review: hypomagnesaemia induced by proton pump inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26108134" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20189276" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A case series of proton pump inhibitor-induced hypomagnesemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27471598" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hypomagnesemia as a potentially life-threatening adverse effect of omeprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27471598" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hypomagnesemia as a potentially life-threatening adverse effect of omeprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4000241" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Calcium absorption and achlorhydria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3006888" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8102318" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22294756" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22294756" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8273984" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24327038" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19262546" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effect of proton pump inhibitors on vitamins and iron.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17344278" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21318590" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Association between proton pump inhibitor use and anemia: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21150767" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27890768" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15455980" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23960351" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Acute interstitial nephritis due to proton pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14742791" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Acute interstitial nephritis due to pantoprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16630752" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Proton pump inhibitors and acute interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24927897" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Biopsy-proven acute interstitial nephritis, 1993-2011: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27080976" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26752337" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20582905" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Analgesic use and the risk for progression of chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17349452" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : NSAID use and progression of chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28583827" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27398293" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27398293" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27398293" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27398293" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32732368" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25341874" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Risk of dementia in elderly patients with the use of proton pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Association of proton pump inhibitors with risk of dementia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28728964" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28128476" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28590010" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31895707" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : No Association Linking Short-Term Proton Pump Inhibitor Use to Dementia: Systematic Review and Meta-analysis of Observational Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17502537" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15507580" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794558" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Proton-pump inhibitor use and the risk for community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21173070" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22956446" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23381076" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19235776" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23856153" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28676480" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
